Table I.
Demographics and Baseline Characteristics
| Characteristics | Total Cohort (N=999) | ABPM Cohorta (N=243) |
|---|---|---|
| Age, mean (SD), y | 55.6 (11.4) | 56.6 (10.1) |
| ≥65 y, No. (%) | 228 (22.8) | 54 (22.2) |
| Women, No. (%) | 491 (49.1) | 113 (46.5) |
| Weight, mean (SD), kg | 88.2 (21.5) | 89.7 (20.8) |
| BMI, mean (SD), kg/m2 | 31.0 (6.4) | 31.4 (6.5) |
| Race, No. (%) | ||
| Caucasian | 630 (63.1) | 169 (69.5) |
| Black | 234 (23.4) | 47 (19.3) |
| Asian | 129 (12.9) | 26 (10.7) |
| American Indian/Alaskan Native | 6 (0.6) | 1 (0.4) |
| Ethnicity, No. (%) | ||
| Hispanic or Latino | 105 (10.5) | 33 (13.6) |
| Type 2 diabetes, No. (%) | 192 (19.2) | 32 (13.2) |
| Metabolic syndrome, No. (%) | 462 (46.2) | 107 (44.0) |
| Prior monotherapy, No. (%) | ||
| ACE inhibitor | 289 (28.9) | – |
| ARB | 237 (23.8) | – |
| Diuretic | 167 (16.7) | – |
| DHP‐CCB | 118 (11.8) | – |
| β‐Blocker | 115 (11.5) | – |
| Non–DHP‐CCB | 20 (2.0) | – |
| Other | 20 (2.0) | – |
| Noneb | 33 (3.3) | – |
| SeSBP, mean (SD), mm Hg | 153.7 (9.2) | 153.5 (8.8) |
| SeDBP, mean (SD), mm Hg | 91.9 (8.6) | 91.3 (7.7) |
| Ambulatory SBP, mean (SD), mm Hg | NA | 135.8 (11.7) |
| Ambulatory DBP, mean (SD), mm Hg | NA | 81.3 (9.0) |
Abbreviations: ABPM, ambulatory blood pressure (BP) monitoring; ACE, angiotensin‐converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; DBP, diastolic BP; DHP‐CCB, dihydropyridine–calcium channel blocker; NA, not available; SBP, systolic BP; SD, standard deviation; Se, seated. aABPM cohort was monitored for 24 hours at baseline, week 12, and week 20. bDid not take antihypertensive therapy within 1 day prior to the first amlodipine/olmesartan medoxomil dose. Note that 11 patients received triamterene/hydrochlorothiazide combination therapy prior to study entry. This was the only combination allowed per protocol due to triamterene’s weak activity and potassium‐sparing effects.